Skip to main content
. Author manuscript; available in PMC: 2016 Jun 3.
Published in final edited form as: Cell. 2009 Aug 13;138(4):645–659. doi: 10.1016/j.cell.2009.06.034

Figure 3. Identification and validation of compounds that exhibit selective toxicity for mesenchymally transdifferentiated epithelial cells.

Figure 3

(a) Chemical structure of salinomycin, etoposide, abamectin, and nigericin and dose-response curves of control HMLE-shCntrl cells and HMLE-shEcad cells treated with indicated compounds. (b) Dose-response curves of the viability of HMLE-shCntrl and HMLE-Twist cells. (c) Dose-response curves of control HMLER and HMLER-shEcad tumorigenic mammary epithelial cells treated with salinomycin, etoposide, abamectin, or nigericin. Each treatment combination was performed in at least 6 replicates.